Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table – Washington Times

The warnings are already up in the popular press: Conversations during the Thanksgiving feast can be hazardous if they veer into political territory. But political talk can take place in theory: A data research company has now determined what topics are safe to talk about on the holiday.

With some qualitative analysis and a little common sense, weve created a cheat sheet that will help you blaze a path through Thanksgiving dinner that steers clear of treacherous political pitfalls and dangerous inter-uncle conflicts, reports Ranker.com, a Los Angeles-based media company which uses crowdsourcing to rank public opinion on multiple topics, typically at the rate of 15 million votes a month.

They have determined what political topics are the least and the most likely to set off a Thanksgiving dinner squabble. Their judgment is based on 300,000 votes from 40,000 respondents.

The topics to avoid this year: Abortion, immigration, terrorism and gender equality. The topics which are safe for dinnertime discussion: Ineffective government, health care reform and education.

If there are millennials present, they will be triggered, the organization says, by talk of abortion, police brutality and pollution. Generation X members will be set off by such topics as homelessness, affordable housing and campaign finance reform. Baby boomers will go to battle over terrorism, immigration and the moral decline of the nation.

The organization also has warnings for dinner hosts in certain states. If they live in Florida, their guests will be particularly sensitive about discussions of vaccines. In Indiana, its gender equality while Georgia diners are prone to fight over police brutality. Beware of talking about gun control at dinner tables in both California and Missouri; Texans get feisty over moral decline. New Yorkers get upset over transgender issues.

We examined each issue on a case-by-case basis to find the topics that are most likely to cause disagreement, as well as the ones on which people tend to either agree or not care about, Ranker.com explains.

A VERY SPECIALIZED MEAL

While most of us are enjoying turkey and pumpkin pie on Thanksgiving, the staff at one laboratory at Cedars-Sinai Medical Center in Los Angeles will be busy serving a meal to stem cells.

Stem cells do not observe national holidays, says Loren Ornelas-Menendez, manager of the very specialized lab that converts samples of adult skin and blood cells into stem cells which the human body uses to make our cells in the first place.

These special cells help medical scientists learn how diseases develop and how they might be cured. The lab is tending millions of them. Oh, but they have needs.

Stem cells are living creatures that must be hand-fed a special formula each day, monitored for defects and maintained at just the right temperature. And that means the cell lab is staffed every day, 52 weeks a year, the lab notes in a public advisory.

Many people have dogs. We have stem cells, says Ms. Ornelas-Menendez.

Derived from hundreds of healthy donors and patients, the resident induced pluripotent stem cells or iSPCs are keys to potential treatments for diabetes, breast cancer, Alzheimers disease, blindness, Parkinsons disease and Crohns disease, among other conditions. Ten lab technicians monitor the cells through microscopes each day and cull out any cells which have gone awry for one reason or another.

But what do they eat even on Thanksgiving?

While the cells get sorted, a special feeding formula is defrosting in a dozen bottles spread around a lab bench. The formula includes sodium, glucose, vitamins and proteins. Using pipettes, employees squeeze the liquid into food wells inside little compartments that contain the iPSCs. Afterward, they return the cells to their incubators, the lab advises.

Lab director Dhruv Sareen suggests that people consider offering a toast to the stem cells on Thanksgiving.

One day the cells they tend could lead to treatments for diseases that have plagued humankind for centuries, he says. And thats something to be truly thankful for.

THE GIPPERS FAVORITE

Back by popular demand, Inside the Beltway again shares this little known but historic recipe for President Reagans Favorite Macaroni and Cheese enjoyed by Ronald Reagan and his family on Thanksgiving and other holidays. What follows is a step-by-step shared by Mrs. Ronald Reagan, Washington, D.C., Wife of the President in a spiral-bound community cookbook published by the American Cancer Societys Northern Virginia division in 1983. The recipe serves six and is baked at 350 degrees F for 45 minutes.

The directions are from the cookbook reflecting the style, perhaps, of another era:

1/2 pound macaroni, 1 teaspoon butter, 1 egg, beaten; 1 teaspoon salt, 1 teaspoon dry mustard, 3 cups grated cheese, sharp; 1 cup milk.

Boil macaroni in water until tender and drain thoroughly. Stir in butter and egg. Mix mustard and salt with 1 tablespoon hot water and add to milk. Add cheese leaving enough to sprinkle on top. Pour into buttered casserole, add milk, sprinkle with cheese. Bake until custard is set and top is crusty.

Curious about what transpired at a Reagan Thanksgiving? A 1985 Los Angeles Times account noted this:

President and Mrs. Reagan gathered with their family for a quiet Thanksgiving dinner at their fogbound ranch in the Santa Ynez mountains, where the main topic of conversation was the weather. The Reagans did not seem to mind the enforced seclusion as they sat down to a traditional turkey dinner, prepared by Ann Allman, the Reagan familys longtime cook in California. It was an all-American menu that included cornbread dressing, cranberries, string beans, mashed potatoes, salad, pumpkin pie and monkey bread, a family favorite.

POLL DU JOUR

46% of Americans say long standing family tensions are the cause of family fights during holidays.

37% say general politics is the cause; 33% cite the 2020 presidential race.

24% say someones future plans cause the fights; 24% say money.

22% say the behavior of guests; 21% say drinking and alcohol.

18% say holiday cooking is the cause.

Source: A YouGov poll of 1,310 U.S. Adults conducted Sept. 25-26 and released Tuesday.

Have a happy Thanksgiving and thank you for reading Inside the Beltway.

Read the original post:
Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times

BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND – BioSpace

BrainStorms Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company is proud to be a gold sponsor of the 30th International Symposium on ALS/MND.

The symposium will take place December 4 6, 2019, at the Perth Convention and Exhibition Centre in Perth, Australia. The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields.

Ralph Kern MD MHSc, BrainStorms Chief Operating and Chief Medical Officer, will deliver a podium presentation: Modulation of innate immunity by MSC-NTF (NurOwn) cells correlates with ALS clinical outcomes, on December 4, from 11:50 12:10 pm AWST during the opening day Clinical Trials Session. In addition to the podium presentation, the Company will also present Poster 153: MSC-NTF Differentiation Increases the Neurotrophic Effects of MSC Cells: Live Imaging Analysis, that directly demonstrates the neuroprotective effects of NurOwn in a neuronal cell culture model.

Our fully-enrolled phase 3 clinical trial is one of the most advanced clinical programs in ALS, stated Chaim Lebovits, President and CEO of BrainStorm. He added, The International Symposium on ALS/MND is an important venue to update the community on our clinical and scientific efforts towards the advancement of therapies that may address the unmet needs of those living with ALS. BrainStorm Cell Therapeutics is proud to serve as a sponsor of this important annual symposium which underscores our commitment to the international community of ALS and MND patients, their families and their caregivers.

Ralph Kern, MD, stated, It is a privilege to present our innovative biomarker and preclinical research at the International Symposium on ALS/MND. He added, Every year, symposium participants gather together and discuss the opportunities and the challenges that we will face during the upcoming year. Research and medical breakthroughs for the ALS and MND community continue to make significant progress and we look forward to sharing our insights and engaging with colleagues from around the globe. The International Symposium on ALS/MND reminds us how far we have come in investigational therapies and how much more progress is still needed to bring patients a better and more promising future.

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields. The Symposium is planned as two parallel meetings, one on biomedical research and the other on advances in the care and management of people affected by ALS/MND. Joint sessions consider issues of mutual concern, challenging current views and practices.

Safe-Harbor Statements

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BRAINSTORM CONTACTS:

Investors:Uri Yablonka, Chief Business OfficerBrainStorm Cell Therapeutics IncPhone: : +1-201-488-0460Email: uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839Email: sean.leous@icrinc.com

Link:
BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace

Canine Stem Cell Therapy Market Value Projected to Expand by 2026 – The Hilltop Monitor

The current Stem Cells Cryopreservation Equipments market research report has demonstrated all the vital market growth factors and economic fluctuations mentioned owing to the vast attention gained in recent years.

The Stem Cell Cartilage Regeneration market report provides a meticulous picture of the sector by summary of data, production, and method of study originated from various sources.

The high numbers of specialized veterinarians and veterinary clinics in these regions also contribute to the promising growth opportunities held by the canine stem cell therapy market in these regions. The market is growing with technological innovation, competition and M&A activities in the industry are offering specific application products for varied end-users.

The report is a thorough analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market.

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. In-depth analysis of numerous components has been studied in the report including supply and demand Figures, cost, price, revenue, gross margins, current geographical zones, technology, demand-supply and consumption. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

The report analyzes the prevalent opportunities for the market's growth and those that companies should capitalize in the near future to strengthen their position in the market.

Common sense to rest Man United seniors for Astana trip: SolskjaerA statement released by the club In February said "everybody looks forward to seeing him wear the red shirt again". Their last outing against Sheffield United ended in 3-3 draw and they surely don't repeat that feat this time.

Global Market portal aims to provide reports like these in order to draw the attention of numerous clients wanting to extrapolate some of the vital details of the Stem Cells Cryopreservation Equipments market on a global scale. The report provides an extensive evaluation of each market segment considering its demand, production, sales revenue, and potential growth. The solid research on the Animal Stem Cell Therapy Market is prepared with the aim to meet the requirements of the customer in terms of the availability of data, analytics, statistics, and an accurate forecast market.The market report also presents the landscape and a corresponding detailed analysis of the major players operating in the market. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length. USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits.

- Which Trending factors influencing the market shares of the top regions across the globe?

- Who are the key market players and what are their strategies in the global Animal Stem Cell Therapy market? Moreover, studies showing the excellent level of safety granted by allogeneic stem cell therapy are also rising in numbers, leading to increased confidence among pet owners as well as veterinarians regarding canine stem cell therapy.

- What industrial trends, drivers and challenges are manipulating its growth?

- What are the key outcomes of the five forces analysis of the global Animal Stem Cell Therapy market? The clients and other readers can have all the global Stem Cells Cryopreservation Equipments market highlights provided in this very report. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the report's forecast period. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. The report has all the vital information regarding supply and demand, market development enhancers, market share, sales distributors, and more advocated in a very formal pattern.

Read the original:
Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor

Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Industry News Info

The Global Stem Cells Market report study includes an elaborative summary of the Stem Cells market that provides in-depth knowledge of various different segmentations. Stem Cells Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Stem Cells Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Stem Cells delivers pin point analysis of varying competition dynamics and keeps ahead of Stem Cells competitors such as CCBC, Vcanbio, Boyalife, Beikebiotech.

View Sample Report @https://www.intenseresearch.com/market-analysis/global-stem-cells-market-2019-by-manufacturers-regions.html#request-sample

The main objective of the Stem Cells report is to guide the user to understand the Stem Cells market in terms of its definition, classification, Stem Cells market potential, latest trends, and the challenges that the Stem Cells market is facing. In-depth researches and Stem Cells studies were done while preparing the Stem Cells report. The Stem Cells readers will find this report very beneficial in understanding the Stem Cells market in detailed. The aspects and information are represented in the Stem Cells report using figures, bar-graphs, pie diagrams, and other visual representations. This intensifies the Stem Cells pictorial representation and also helps in getting the Stem Cells industry facts much better.

.This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, the USA, the UK, and Japan. The present, past and forecast overview of the Stem Cells market is represented in this report.

The Study is segmented by following Product Type, Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Major applications/end-users industry are as follows Diseases Therapy, Healthcare

Stem Cells Market Report Highlights:

1)The report provides a detailed analysis of current and future market trends to identify the investment opportunities2) In-depth company profiles of key players and upcoming prominent players3) Global Stem Cells Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4) Strategic recommendations in key business segments based on the market estimations5) To get the research methodologies those are being collected by Stem Cells driving individual organizations.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involve the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In Secondary research crucial information about the industry value chain, the total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Inquiry for Buying Report: https://www.intenseresearch.com/market-analysis/global-stem-cells-market-2019-by-manufacturers-regions.html#inquiry-for-buying

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

More here:
Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info

Lulu and Nana are the result of a defiant experiment in human gene modification – The Irish Times

Remember these two names, Lulu and Nana. They are twin girls born in China in October 2018, and we already know they are going to be famous.

They are the worlds first genetically-edited humans, and their progress through life will be monitored intensively by medical researchers over the coming years.

Dont doubt their future celebrity. Remember the headlines when Dolly the sheep arrived in 1996, the worlds first mammal cloned directly from an adult cell. Or how about Louise Brown, who made headlines in 1978 as the first baby to be conceived using invitro fertilisation (IVF) techniques.

Although the methods used to bring about these three births are light years apart, all three involve the delivery of an offspring using unorthodox methods.

All three were also controversial in their day. There was no end of condemnation and criticism about playing god and defying the laws of nature for the first two, but now IVF is commonplace for lots of medical reasons and is accepted as a standard medical practice. And news of another species successfully cloned in the lab would not make headlines today.

However, the genetic modification of the twins is a different matter, a genetic change introduced before birth to deliver a permanent alteration of their original genome that will be passed down from generation to generation.

Prof He Jiankui of the Southern University of Science and Technology carried out the genetic change needed to permanently modify the twins genome. He introduced a mutation that gave Lulu and Nana resistance to the Human Immunodeficiency Virus, the virus that causes Aids, and revealed his successful genetic modification one year ago this month.

The backlash was immediate and severe. There was international condemnation that China allowed experimentation on humans. Last January his university sacked him.

The scientific community also criticised the work as having crossed an important red line for genetics research, the reality that we still know too little about how even the smallest genetic change might have unexpected impacts downstream in other parts of the genome.

It was bad enough that a modification had taken place, but the modification was in the germline, the cells that bring about the next generation and the next and the next.

Perhaps the lure of notoriety proved too strong or the desire to be the first, but He Jiankui crossed that line, helped along the way through use of a gene-editing method known as CRISPR-Cas9.

This method emerged over several years, and has become the gene-cutting tool of choice because it allows very tight control over how a gene can be modified, added to or deleted.

When it came into widespread use the scientific community recognised immediately that controls on its application were necessary to prevent its use in human gene modification. This should have prevented He Jiankui from attempting such a daring and defiant experiment but it didnt, and Lulu and Nana were the result.

They were born healthy but now scientists will want to know whether there are unexpected or unwanted effects or other issues that arise. Already researchers have raised doubts about the gene modification that confers resistance to HIV, which means some level of susceptibility to the virus may remain.

The modified gene, known as CCR5, also has other roles in the body, and its modified actions may affect the lifespan of the twins. One large study involving 410,000 subjects showed that people with a similar mutated version of CCR5 were 20 per cent more likely to die before reaching the age of 78.

Despite these misgivings there is no doubt that CRISPR-Cas9 will in the future be used to modify the human genome in the battle against difficult diseases such as cancer and in genetic disorders caused by specific gene mutations. The tool is far too important to avoid its eventual use, or the use of some other similar but as yet unidentified gene-cutting method.

Similarly there is little doubt that online charlatans will offer promised but undeliverable cures using CRISPR-Cas9, as was the case with earlier technologies such as stem cells.

Lulu and Nana, meanwhile, will get on with living their lives, doing what babies do. Their names are pseudonyms in an attempt to conceal them from public view, but it is likely that we may learn their real names in the future.

Lulu and Nanas story came to mind in light of research published last week (November 21st) in the journal Cell about how attempting to create designer babies using other advanced technology could still remain a costly waste of time.

It involves choosing an embryo based on its potential to be tall or smarter than average, but accomplishing this via something like CRISPR-Cas9 is too far beyond our current abilities. Instead the international team of scientists set up a model to simulate one method called pre-implantation genetic testing.

This involves screening the genome for genes that have an association to a given trait, in this studys case intelligence and height, and giving them a score. The team found, however, that at best the top-scoring embryo might be expected to be 2.5cm taller than average and at best 2.5 IQ points above average.

Lurking behind all of this remains the most challenging of issues, the ethics surrounding the use of this technology.

As usual the ethics questions that should have been asked first are the ones obscured by the advance of these promising discoveries.

Continued here:
Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times

Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 – Med News Ledger

Stem Cell Banking Market Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 20192026Overview: Stem cells are undifferentiated biological cells that can distinguish into specialized cells, tissue, or an organ. The process of storing these stem cells for the treatment of life-threatening diseases in the future is called stem cell banking. Nearly 500 stem cell banks are functioning globally, and every bank is now striving harder to increase their market share. Stem cell banking has applications in cerebral palsy, thalassemia, leukemia, diabetes, autism, and others. Cerebral palsy holds the major share of nearly quarter of the market share among the various applications. Private stem cell banks are implementing innumerable publicizing strategies to upsurge their product visibility among people.

Key Players: Esperite, Caladrius Biosciences, Via Cord, CBR Systems, Smart Cells, Life Cell, China Cord Blood, Cryo-Cell, StemCyte, Cordvida, ViaCord, Cryoviva, and other predominate & niche players.

Get Sample copy of this Report: http://contrivedatuminsights.com/Home/RequestaSample/2433

The market is driven by factors such as easy method of extraction of stem cells from the samples, increasing birth rate, increased awareness of stem cell therapeutics, and increasing potentials of stem cell treatment. Alongside, the collaboration among the cord blood banks, increasing investments and fundings, and automation of procedures for the banking of stem cells are providing opportunities for the growth of the stem cell banking market. However, intense competition, high operating costs, changes in legal regulations, and high entry barriers are the major factors hampering the market growth.

Market Analysis: The Stem Cell Banking Market is estimated to witness a CAGR of 16.4% during the forecast period 20192026. The market is analyzed based on three segments, namely product types, end-users, and regions.Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the stem cell banking market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India, China, and Japan are set to be the most attractive destinations due to the large untapped market.

Product Types Analysis: The stem cell banking market by products is segmented into umbilical cord blood & cord tissue, and adult stem cell banking. The umbilical cord blood & tissue occupies the major share in the market and is also expected to grow at a fast CAGR during the forecast period. The dental stem cell banking and menstrual blood stem cell banking are the latest diversifications in the stem cell banking market. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the global stem cell banking market.

Get Special Pricing: http://contrivedatuminsights.com/Home/GetSpecialPricing/2433

Competitive Analysis: These days, stem cell banks exist in most of the developed and developing nations. Around 450 companies are publicizing cord blood banking services internationally, which signifies intense competition in the market. Globally, China Cord Blood Corporation (CCBC) is expected to be the fastest growing stem cell bank worldwide and in the US, it is Amricord. In 2014, the company Amricord achieved 2,200% growth rate from 2011-2013. Future Health Biobank, American Cryostem, Adicyte, Adisave, Celltex, and Vault Stem currently hold around two-thirds of the Mesenchymal Stem Cells (MSC) storage market. However, at present, these companies are still trivial but are swiftly intensifying. Cryostem witnessed its revenue to nearly double in 2016 from $400,000 to almost $800,000.

Benefits: The report provides complete details about the usage and adoption rate of stem cell banking in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives toward the stem cell therapy and banking adoption in the upcoming years along with the details of commercial devices available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyse before investing or expanding the business in this market.

For More Information: http://contrivedatuminsights.com/Home/InquiryBeforeBuying/2433

Table of Contents

Global Stem Cell Banking Market Research Report

Chapter 1 Global Stem Cell Banking Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Market Forecast

Any special requirements about this report, please let us know and we can provide custom report.

View post:
Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger

Why Stem Cell Therapy Might Be Your Answer To Chronic Pain – Patch.com

This article is sponsored by The Art of Pain Management and Regenerative Medicine.

Having performed more than 25,000 procedures throughout the last decade, Dr. Jarrad Teller and Dr. Michael Schina of the Art of Pain Management (AOPM) are just getting started. Ten years ago, Dr. Teller, a chiropractor with degrees in physiotherapy and kinesiology, partnered with Dr. Schina, a vascular and trauma surgeon. Together, the pair has created one of the most successful interventional pain management practices in the tri-state area thanks to their multifaceted approach to patients. Modalities of treatment that are used by AOPM include yoga, meditation, vitamins and herbs, diet programs and spine and joint injections.

"Two years ago, our office began using stem cells to treat arthritic conditions. Previously, injections with cortisone and local anesthetic temporarily relieved a patient's pain. With stem cell injections, the patient's injury began to heal and osteoarthritis improved."

Stem cell therapy utilizes multi-potent cells that are capable of differentiating and growing into various types of tissue in the body. Stem cells act as beacon cells that find areas of inflammation (areas of need in the body) and reprogram the body's own stem cells to regenerate tissue. Stem cell function requires a healthy milieu. That is why blood analysis and correction of abnormalities prior to stem cell therapy is so important.

Osteoarthritis of the spine (neck and back), shoulder, knee, hip and ankle are the most common conditions that AOPM treats. Other conditions for which patients seek treatment include COPD, autoimmune disorders and spinal injuries, in addition to unexplained illnesses.

With traditional pain management that utilizes cortisone injections, yoga, meditation, lifestyle changes and diet, about half of patients fail to improve. This is largely related to the fact that cortisone treats only the patient's symptoms and does nothing to alleviate the underlying osteoarthritis. For the other half of patients, stem cell therapy offers the potential to improve the osteoarthritis by regenerating tissue and may be a viable option.

Art of Pain Management and Regenerative Medicine

3300 Grant Ave. Philadelphia, PA 19114

610-352-1710

See the rest here:
Why Stem Cell Therapy Might Be Your Answer To Chronic Pain - Patch.com

Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia – Cancer Therapy Advisor

A recent analysis of treatment options for patients with mixed-phenotype acute leukemia (MPAL) suggests favorable outcomes may be obtained with frontline therapy using a chemotherapy regimen usually administered to patients with acute lymphoblastic leukemia (ALL) and without hematopoietic stem cell transplantation (HSCT). Results of this analysis were published in Cancer.

In this central review of MPAL outcomes, the Childrens Oncology Group Acute Leukemia of Ambiguous Lineage Task Force studied a cohort of 54 patients aged 1 to 30 years with diagnoses of MPAL who were enrolled in clinical trials involving ALL or acute myeloid leukemia (AML) treatments.

Induction therapies typically consisted of ALL treatment regimens, AML treatment regimens, or a hybrid of both approaches. A variety of postinduction treatment options, with or without HSCT, were also included.

Patients with MPAL who were given ALL (72%) or AML (24%) induction treatments did not significantly differ from each other in reported baseline characteristics.

End-of-induction complete remission was achieved by 72% of patients treated with an ALL induction regimen and by 69% of patient given an AML induction regimen.

Among all patients in the cohort, the 5-year overall survival rate was 77%; among patients who received ALL chemotherapy without HSCT, the 5-year overall survival rate was 84%. The 5-year event-free survival rate was 72% for the total cohort and 75% among those who received ALL chemotherapy without HSCT.

The researchers stated that their findings demonstrated that durable remissions are possible for a subset of patients with MPAL receiving ALL chemotherapy without HSCT consolidation. They also described a forthcoming prospective clinical trial that will test a minimum residual disease-guided treatment approach with ALL therapy and without HSCT in patients with MPAL.

Reference

This article originally appeared on Hematology Advisor

Link:
Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia - Cancer Therapy Advisor

North-east toddler overcomes cancer after pioneering stem cell treatment – Press and Journal

It may finally be a happy Christmas for a brave toddler recovering from a rare combination of cancers after pioneering stem cell treatment.

Amelia Topa, who celebrated her second birthday yesterday, is looking forward to spending the festive period with her family at home in Turriff.

Her parents Kerri Paton, 23, and Igor Topa, 24, were told that raised purple spots across Amelias body could be a sign of something seriously wrong when she was born at Dr Grays Hospital in Elgin.

Amelia was soon after diagnosed with a mix of two types of leukemia acute lymphoblastic leukaemia and acute myeloid leukaemia and spent Christmas in hospital.

Miss Paton said: Its rare enough to be born with leukaemia but to be born with a mix of two kinds is almost unheard of.

Doctors gave Amelia a bone marrow transplant using stem cells donated by a managed between 16 and 30.

The treatment worked and, by the following autumn, she was home and awaiting the arrival of her baby brother.

But tragedy struck when Amelias grandmother, Angela McNabb, died suddenly from heart failure aged 48 the day before Amelias birthday.

Miss Paton said: My mum was my best friend, she was everything to me.

Mum absolutely loved Amelia and was so close to her.

My major source of support was gone and I hadnt even had the chance to say goodbye. I couldnt believe it. It was so unfair. Last Christmas was heartbreaking.

Things went from bad to worse for the family in February, when tests showed that Amelias cancer had returned.

After intense chemotherapy she was given a second transplant using stem cells from umbilical cord blood flown specially from America at the end of June.

That procedure was a success and the toddler has entered remission.

Having spent Christmas in 2017 in hospital, and in mourning last year, Amelias parents are now looking forward to a happy festive season.

Miss Paton said: Amelia soared through the transplant and shes doing really well now,I couldnt be prouder.

I hope Amelias story will help other families going through cancer there is a light at the end of the tunnel.

Amelia has now been selected to receive the first Cancer Research UK children and young people star award in recognition of the courage she showed since being diagnosed.

The award, supported by TK Maxx, is open to all people under 18s who currently have cancer or who have been treated in the last five years with every child being awarded a trophy, TK Maxx gift card, t-shirt and certificate signed by the likes of Nanny McPhee star Dame Emma Thompson.

Spokeswoman for the charity, Lisa Adams, said: We know that a cancer diagnosis is devastating at any age, but that it can be particularly difficult for a child or young person and their families.

Thats why were calling on families across Scotland to nominate inspirational youngsters for an award so that we can recognise their incredible courage.

Nominations can be made online at cruk.org/childrenandyoungpeople

Read the original post:
North-east toddler overcomes cancer after pioneering stem cell treatment - Press and Journal

Revolutionary stem cell banking and therapy from Celltex gives patients hope – KHOU.com

HOUSTON Diseases like arthritis, multiple sclerosis, ALS, Parkinson's, Alzheimer's have no cure, but with a revolutionary procedure from Celltex patients see a dramatic difference in their livelihood.

Celltex chairman and CEO, David Eller, talked with Deborah Duncan about how the company is leading breakthroughs in regenerative medicine. Celltex has a proprietary technology that isolates, grows and cryopreserves hundreds of millions of one's own stem cells.

Stem cells are extracted from an individual's own fat. It is multiplied and cryopreserved for future therapy, only for the patient. The cells are stored in a U.S.-based, FDA registered lab until treatment. Celltex works with established, certified hospitals in Mexico, until stem cell therapy is legalized in the United States. Treatments are administered by licensed physicians. These stem cells can relieve a variety of chronic conditions and improve quality of life for these patients.

Debbie Bertrand was diagnosed with multiple sclerosis in 2001. The MS made it difficult for her to walk and use her hands. She had numbness in her feet, loss of balance, drop foot and had to use a wheelchair in public.

Bertrand learned about Celltex and banked her stem cells in 2011. She's had several rounds of treatment, and after each treatment, she's seen great improvement.

Bertrand had no side effects from the stem cell therapy. She has reduced the number of MS medications she takes from five to two. She no longer has to use a wheelchair and uses a walker to walk. She has improved so much, she is able to walk 6,000 to 8,000 steps each day. Bertrand has a more normal gait, has better circulation in her hands and feet, and has increased energy, strength and alertness.

To make an appointment with Celltex, call 713-590-1000. For more information, log on to CelltexBank.com.

For more on Celltex's upcoming informational seminars, click here.

To see an online webinar from Celltex, click here.

This content is sponsored by: Celltex.

Link:
Revolutionary stem cell banking and therapy from Celltex gives patients hope - KHOU.com